Arar Pharmaceutical Research Center Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 8 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
About Arar Pharmaceutical Research Center
Arar Pharmaceutical Research Center Private Limited (APRCPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 10 June 2016 (Eight years and eight months 4 days old ). Its registered office is in Belgaum, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹1.00 M.
Ramdas Raikar and Rina Raikar serve as directors at the Company.
Company Details
-
Location
Belgaum, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24290KA2016PTC094054
-
Company No.
094054
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Jun 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Arar Pharmaceutical Research Center?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramdas Raikar
|
Director | 10-Jun-2016 | Current |
|
Rina Raikar
|
Director | 02-Sep-2021 | Current |
Financial Performance of Arar Pharmaceutical Research Center.
Arar Pharmaceutical Research Center Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arar Pharmaceutical Research Center?
In 2017, Arar Pharmaceutical Research Center had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 May 2023 | Others | ₹1.00 M | Open |
How Many Employees Work at Arar Pharmaceutical Research Center?
Arar Pharmaceutical Research Center has a workforce of 12 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arar Pharmaceutical Research Center, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arar Pharmaceutical Research Center's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
